Cargando…
EZH2 inhibitor GSK343 inhibits sepsis-induced intestinal disorders
Enhancer of zeste homolog 2 (EZH2) is positively associated with poor clinical outcomes in a number of aggressive tumors. Recent studies have demonstrated that inhibition of EZH2 also suppressed the inflammatory response during sepsis. The present study aimed to investigate whether an inhibitor of E...
Autores principales: | Yue, Dongyou, Wang, Zhiying, Yang, Yongan, Hu, Zhenjun, Luo, Ganping, Wang, Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967880/ https://www.ncbi.nlm.nih.gov/pubmed/33747174 http://dx.doi.org/10.3892/etm.2021.9854 |
Ejemplares similares
-
The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
por: Yu, Tianfu, et al.
Publicado: (2017) -
In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes
por: Liu, Tsang-Pai, et al.
Publicado: (2016) -
Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism
por: Pereira, Adriana S. A., et al.
Publicado: (2018) -
Neuroprotective effects of GSK-343 in an in vivo model of MPTP-induced nigrostriatal degeneration
por: Mannino, Deborah, et al.
Publicado: (2023) -
Treatment of calcific arterial disease via enhancement of autophagy using GSK343
por: Lino Cardenas, Christian L., et al.
Publicado: (2023)